Clin Mol Hepatol.
2024 Apr;30(2):166-167. 10.3350/cmh.2024.0128.
JCAD, a new potential therapeutic target in cholestatic liver disease
- Affiliations
-
- 1Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea
- KMID: 2554421
- DOI: http://doi.org/10.3350/cmh.2024.0128
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis
- Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”
- Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances
- A Case of Steven-Johnson Syndroe Associated with Cholestatic Hepatitis
- Four cases of ticlopidine-induced cholestatic hepatitis
